Nav: Home

No link found between erectile dysfunction drugs and risk of prostate cancer

August 01, 2016

New York, NY, August 1, 2016 - While some previous studies have indicated that taking erectile dysfunction (ED) drugs may reduce the likelihood of developing prostate cancer, new research published in The Journal of Urology® found that these drugs do not play a role in preventing prostate cancer.

ED is a common problem with a prevalence of 20% to 40% in the sixth decade of life and approaching 75% in the seventh decade. Drugs such as tadalafil, sildenafil, and vardenafil are phosphodiesterase type 5 inhibitors (PDE-5is) commonly used to treat ED. Since PDE-5is were first introduced in 1998, their durability, safety, and efficacy for treating ED have been clearly demonstrated.

"In vitro mouse studies have suggested that these drugs might have some anticancer activity, but the evidence in human subjects is mixed," said lead investigator Stephen J. Freedland, MD, Division of Urology, Department of Surgery at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai in Los Angeles, CA. "Given the routine use of PDE-5i and the possibility that these agents may have anticancer activity, we wanted to test the association between their use and risk of developing prostate cancer."

Using data from REDUCE, a four-year, multicenter study testing the effect of daily dutasteride to treat benign prostatic hyperplasia on prostate cancer risk in men, the authors analyzed whether ED drug use by more than 6,500 patients may have affected overall prostate cancer risk and disease grade (Gleason 2-6 and 7-10). All participants in the REDUCE study were required to undergo biopsies at two and four years after enrollment, which facilitated uniform cancer assessments across the entire group. In this way, the basic science linking PDE-5i and anticancer activity could be explored.

Of the 6,501 men in the study 364 (5.6%) used PDE-5i at baseline. During the study, prostate cancer was diagnosed in 71 of these men (19.5%) compared to 1,391 of 6,137 (22.7%) men who did not take PDE-5i, which was not significantly different. An analysis of prostate cancer grade also showed no correlation between PDE-5i use and low or high grade cancer. Because PDE-5i use was significantly higher among North American men, the authors looked for a regional effect. They found some correlation between ED use and lower prostate cancer diagnosis in North American men, but this did not reach statistical significance.

"Future studies with longer followup and larger study populations are warranted to determine the association between PDE-5i and prostate cancer," said Juzar Jamnagerwalla, MD, urology resident at Cedars-Sinai and first author of the study.
-end-


Elsevier Health Sciences

Related Prostate Cancer Articles:

ASCO and Cancer Care Ontario update guideline on radiation therapy for prostate cancer
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer.
Patient prostate tissue used to create unique model of prostate cancer biology
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
Moffitt Cancer Center awarded $3.2 million grant to study bone metastasis in prostate cancer
Moffitt researchers David Basanta, Ph.D., and Conor Lynch, Ph.D., have been awarded a U01 grant to investigate prostate cancer metastasis.
New findings concerning hereditary prostate cancer
For the first time ever, researchers have differentiated the risks of developing indolent or aggressive prostate cancer in men with a family history of the disease.
Prostate cancer discovery may make it easier to kill cancer cells
A newly discovered connection between two common prostate cancer treatments may soon make prostate cancer cells easier to destroy.
New test for prostate cancer significantly improves prostate cancer screening
A study from Karolinska Institutet in Sweden shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
The dilemma of screening for prostate cancer
Primary care providers are put in a difficult position when screening their male patients for prostate cancer -- some guidelines suggest that testing the general population lacks evidence whereas others state that it is appropriate in certain patients.
Risk factors for prostate cancer
New research suggests that age, race and family history are the biggest risk factors for a man to develop prostate cancer, although high blood pressure, high cholesterol, vitamin D deficiency, inflammation of prostate, and vasectomy also add to the risk.
Prostate cancer is 5 different diseases
Cancer Research UK scientists have for the first time identified that there are five distinct types of prostate cancer and found a way to distinguish between them, according to a landmark study published today in EBioMedicine.
UH Seidman Cancer Center performs first-ever prostate cancer treatment
The radiation oncology team at UH Seidman Cancer Center in Cleveland performed the first-ever prostate cancer treatment April 3 using a newly-approved device -- SpaceOAR which enhances the efficacy of radiation treatment by protecting organs surrounding the prostate.

Related Prostate Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#529 Do You Really Want to Find Out Who's Your Daddy?
At least some of you by now have probably spit into a tube and mailed it off to find out who your closest relatives are, where you might be from, and what terrible diseases might await you. But what exactly did you find out? And what did you give away? In this live panel at Awesome Con we bring in science writer Tina Saey to talk about all her DNA testing, and bioethicist Debra Mathews, to determine whether Tina should have done it at all. Related links: What FamilyTreeDNA sharing genetic data with police means for you Crime solvers embraced...